International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(12), P. 6733 - 6733
Published: June 19, 2024
Glioblastoma
is
the
most
common
and
lethal
central
nervous
system
malignancy
with
a
median
survival
after
progression
of
only
6–9
months.
Major
biochemical
mechanisms
implicated
in
glioblastoma
recurrence
include
aberrant
molecular
pathways,
recurrence-inducing
tumor
microenvironment,
epigenetic
modifications.
Contemporary
standard-of-care
(surgery,
radiation,
chemotherapy,
treating
fields)
helps
to
control
primary
but
rarely
prevents
relapse.
Cytoreductive
treatment
such
as
surgery
has
shown
benefits
recurrent
glioblastoma;
however,
its
use
remains
controversial.
Several
innovative
treatments
are
emerging
for
glioblastoma,
including
checkpoint
inhibitors,
chimeric
antigen
receptor
T
cell
therapy,
oncolytic
virotherapy,
nanoparticle
delivery,
laser
interstitial
thermal
photodynamic
therapy.
This
review
seeks
provide
readers
an
overview
(1)
recent
discoveries
basis
recurrence;
(2)
role
(3)
novel
paradigms
glioblastoma.
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(13), P. 7207 - 7207
Published: June 29, 2022
(1)
Background:
Glioblastoma
is
the
most
frequent
and
lethal
primary
tumor
of
central
nervous
system.
Through
many
years,
research
has
brought
various
advances
in
glioblastoma
treatment.
At
this
time,
management
based
on
maximal
safe
surgical
resection,
radiotherapy,
chemotherapy
with
temozolomide.
Recently,
bevacizumab
been
added
to
treatment
arsenal
for
recurrent
scenario.
Nevertheless,
patients
still
have
a
poor
prognosis.
Therefore,
efforts
are
being
made
different
clinical
areas
find
new
alternative
improve
overall
survival,
free-progression
life
quality
patients.
(2)
Methods:
Our
objective
recap
actual
state-of-the-art
treatment,
resume
future
perspectives
immunotherapy,
as
well
synthetic
molecules
natural
compounds
that
represent
potential
therapies
at
preclinical
stages.
(3)
Conclusions:
Despite
great
therapeutic
research,
suffered
minimal
changes,
prognosis
remains
poor.
Combined
strategies
delivery
methods,
including
molecules,
compounds,
stem
cell
inhibition,
may
potentiate
standard
care
therapy
next
step
research.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(6), P. 5435 - 5447
Published: March 16, 2023
Postsurgical
treatment
of
glioblastoma
multiforme
(GBM)
by
systemic
chemotherapy
and
radiotherapy
is
often
inefficient.
Tumor
cells
infiltrating
deeply
into
the
brain
parenchyma
are
significant
obstacles
to
eradication
GBM.
Here,
we
present
a
potential
solution
this
challenge
introducing
an
injectable
thermoresponsive
hydrogel
nanocomposite.
As
liquid
that
contains
drug-loaded
micelles
water-dispersible
ferrimagnetic
iron
oxide
nanocubes
(wFIONs),
nanocomposite
injected
resected
tumor
site
after
surgery.
It
promptly
gelates
at
body
temperature
serve
as
soft,
deep
intracortical
drug
reservoir.
The
target
residual
GBM
deliver
drugs
with
minimum
premature
release.
Alternating
magnetic
fields
accelerate
diffusion
through
heat
generation
from
wFIONs,
enabling
penetrative
delivery.
Significantly
suppressed
growth
improved
survival
rates
demonstrated
in
orthotopic
mouse
model.
Our
system
proves
platform
for
postsurgical
treatment.
The Journal of Cell Biology,
Journal Year:
2023,
Volume and Issue:
222(3)
Published: Feb. 16, 2023
Mammalian
genes
were
long
thought
to
be
constrained
within
somatic
cells
in
most
cell
types.
This
concept
was
challenged
recently
when
cellular
organelles
including
mitochondria
shown
move
between
mammalian
culture
via
cytoplasmic
bridges.
Recent
research
animals
indicates
transfer
of
cancer
and
during
lung
injury
vivo,
with
considerable
functional
consequences.
Since
these
pioneering
discoveries,
many
studies
have
confirmed
horizontal
mitochondrial
(HMT)
its
characteristics
consequences
been
described.
Additional
support
for
this
phenomenon
has
come
from
phylogenetic
studies.
Apparently,
trafficking
occurs
more
frequently
than
previously
contributes
diverse
processes
bioenergetic
crosstalk
homeostasis,
disease
treatment
recovery,
development
resistance
therapy.
Here
we
highlight
current
knowledge
HMT
cells,
focusing
primarily
on
vivo
systems,
contend
that
process
is
not
only
(patho)physiologically
relevant,
but
also
can
exploited
the
design
novel
therapeutic
approaches.
Stem Cell Reviews and Reports,
Journal Year:
2023,
Volume and Issue:
19(5), P. 1214 - 1231
Published: April 14, 2023
Abstract
Mesenchymal
stem
cells
(MSCs)
are
regarded
as
highly
promising
for
allogeneic
cell
therapy,
owing
to
their
multipotent
nature
and
ability
display
potent
varied
functions
in
different
diseases.
The
of
MSCs,
including
native
immunomodulation,
high
self-renewal
characteristic,
secretory
trophic
properties,
can
be
employed
improve
the
immune-modulatory
MSCs
impact
most
immune
by
directly
contacting
and/or
secreting
positive
microenvironmental
factors
influence
them.
Previous
studies
have
reported
that
immunomodulatory
role
is
basically
dependent
on
secretion
from
MSCs.
This
review
discusses
capabilities
strategies
successfully
potential
utilization
clinical
research.
Graphical
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(19)
Published: March 13, 2024
Abstract
Temozolomide
(TMZ)
resistance
remains
the
major
obstacle
in
treatment
of
glioblastoma
(GBM).
Lactylation
is
a
novel
post‐translational
modification
that
involved
various
tumors.
However,
whether
lactylation
plays
role
GBM
TMZ
unclear.
Here
it
found
histone
H3K9
(H3K9la)
confers
via
LUC7L2‐mediated
intron
7
retention
MLH1.
Mechanistically,
upregulated
recurrent
tissues
and
TMZ‐resistant
cells,
mainly
concentrated
H3K9.
Combined
multi‐omics
analysis,
including
CUT&Tag,
SLAM‐seq,
RNA‐seq,
reveals
significantly
enriched
LUC7L2
promoter
activates
transcription
to
promote
its
expression.
mediates
MLH1
reduce
expression,
thereby
inhibit
mismatch
repair
(MMR),
ultimately
leading
resistance.
Of
note,
identified
clinical
anti‐epileptic
drug,
stiripentol,
which
can
cross
blood–brain
barrier
lactate
dehydrogenase
A/B
(LDHA/B)
activity,
acts
as
inhibitor
renders
cells
more
sensitive
vitro
vivo.
These
findings
not
only
shed
light
on
mechanism
but
also
provide
potential
combined
therapeutic
strategy
for
treatment.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(3), P. 994 - 994
Published: Jan. 24, 2025
Glioblastoma,
an
aggressive
cancer,
is
difficult
to
treat
due
its
location,
late
detection,
drug
resistance,
and
poor
absorption
of
chemotherapeutics.
Intratumoral
administration
offers
a
promising
potential
treatment
alternative
with
localized
delivery
minimal
systemic
toxicity.
Vanadium(V)
coordination
complexes,
incorporating
Schiff
base
catecholate
ligands,
have
shown
effects
as
antiproliferative
agents
tunable
efficacy
reactivity,
stability,
steric
bulk,
hydrophobicity,
uptake,
toxicity
optimized
for
the
intratumoral
vehicle.
A
new
series
oxovanadium(V)
base–catecholate
complexes
were
synthesized
characterized
using
nuclear
magnetic
resonance
(NMR),
UV-Vis,
infrared
spectroscopy
mass
spectrometry.
Stability
under
physiological
conditions
was
assessed
via
UV-Vis
spectroscopy,
activity
evaluated
in
T98G
glioblastoma
SVG
p12
normal
glial
cells
viability
assays.
The
newly
[VO(3-tBuHSHED)(TIPCAT)]
complex
more
stable
(t1/2
~
4.5
h)
had
strong
(IC50
1.5
µM),
comparing
favorably
current
lead
compound,
[VO(HSHED)(DTB)].
structural
modifications
enhanced
bulk
through
substitution
iso-propyl
tert-butyl
groups.
improved
properties
attributed
hindrance
associated
catecholato
well
formation
non-toxic
byproducts
upon
degradation.
emerges
candidate
therapy
by
demonstrating
stability
greater
selectivity,
which
highlights
role
strategic
ligand
design
developing
therapies
resistant
cancers.
In
reporting
class
compounds
effective
against
cells,
we
describe
generally
desirable
that
drugs
being
developed
should
have.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 24, 2025
Abstract
Glioblastoma
multiforme
(GBM)
is
a
highly
aggressive
and
malignant
brain
tumor
originating
from
glial
cells,
characterized
by
high
recurrence
rates
poor
patient
prognosis.
The
heterogeneity
complex
biology
of
GBM,
coupled
with
the
protective
nature
blood–brain
barrier
(BBB),
significantly
limit
efficacy
traditional
therapies.
rapid
development
nanoenzyme
technology
presents
promising
therapeutic
paradigm
for
rational
targeted
treatment
GBM.
In
this
review,
underlying
mechanisms
GBM
pathogenesis
are
comprehensively
discussed,
emphasizing
impact
BBB
on
strategies.
Recent
advances
in
nanoenzyme‐based
approaches
therapy
explored,
highlighting
how
these
nanoenzymes
enhance
various
modalities
through
their
multifunctional
capabilities
potential
precise
drug
delivery.
Finally,
challenges
prospects
translating
laboratory
research
to
clinical
application,
including
issues
stability,
targeting
efficiency,
safety,
regulatory
hurdles
critically
analyzed.
By
providing
thorough
understanding
both
opportunities
obstacles
associated
therapies,
future
directions
aimed
be
informed
contribute
more
effective
treatments
